Azelis Group N.v. · EURONEXT:AZE
Azelis — Q3 2025 Earnings Presentation
15 slides from Azelis's earnings presentation, Oct 23, 2025
Slide 1: 9M 2025 update
9M 2025 update 23 October 2025
Slide 2: Agenda
Agenda • Key developments & business update • Financial performance • Outlook • Q&A Anna Bertona Thijs Bakker Group CEO Group CFO 9M 2025 update | 23 October 2025
Slide 3: Disclaimer
Disclaimer • This document may contain statements relevant to Azelis Group NV (the “Company”) and/or its affiliated companies (collectively “Azelis” or the “Azelis Group”) which are not historical facts and are hereby identified as “forward-looking statements”. Such forward-looking statements includ
Slide 4: Key developments & business update
Key developments & business update 9M 2025 update | 23 October 2025
Slide 5: Strong cash generation underscores the resilience of our business
Strong cash generation underscores the resilience of our business Higher cash generation as we focus on aligning our working capital investments with demand, 1 reaffirming resilient, strong cash generation capacity of the business model. Ramp-up of cost savings provide protection 2 whilst uncertaint
Slide 6: 9M 2025 highlights
Solid cash discipline in volatile markets • Revenue of EUR 3.2bn, with 2.7% revenue growth contribution from acquisitions offsetting a 0.6% organic decline and a 3.0% FX headwind. • Gross profit margin of 23.7%, reflecting negative mix effect from the 9M 2025 highlights Group's less mature businesse
Slide 7: Growth drivers: Organic and M&A
Growth drivers Organic M&A End markets: Mixed LS, weak IC Azelis is selectively executing on the most strategic • Continued positive momentum in Pharma M&A opportunities • F&N: positive in the US, offsetting weakness in EMEA • Solchem expands the Group’s presence in the highly • A&ES: stable across
Slide 8: Financial performance
Financial performance 9M 2025 update | 23 October 2025
Slide 9: Headline P&L 9M 2025
Headline P&L 9M 2025 Azelis Group highlights Constant Q3 2025 Q3 2024 Change 9M 2025 9M 2024 Change (EUR m) currency Life Sciences 651.5 661.2 -1.5% 2,001.3 2,009.5 -0.4% 2.4% Industrial Chemicals 363.0 393.0 -7.6% 1,172.2 1,190.3 -1.5% 1.7% Group revenue 1,014.6 1,054.2 -3.8% 3,173.5 3,199.9 -0.8%
Slide 10: Headline growth 9M 2025
Headline growth 9M 2025 Organic Total F/X M&A growth Organic Total Q3 2025 Q3 2024 (in millions of €) 9M 2025 9M 2024 growth growth translation contribution growth growth 456.8 438.3 -5.6% 4.2% EMEA 1,435.9 1,355.5 -1.3% 5.8% 1.4% 5.9% 360.7 392.7 -2.2% -8.1% Americas 1,120.4 1,179.4 -4.1% 0.1% -1.0
Slide 11: Regional financial update
Regional financial update EMEA Americas Asia Pacific Adjusted Adjusted Adjusted 13.3% 12.2% 12.7% 11.3% 9.9% 9.6% EBITA EBITA EBITA margin margin margin +5.9% -5.0% € 1 436 € 1 356 € 1 179 -7.2% € 1 120 Revenue Revenue Revenue € 665 € 617 (EUR m) (EUR m) (EUR m) Conversion 51.3% 48.0% Conversion 51.
Slide 12: Working capital
Working capital Working capital Evolution of NWC* EUR million Receivables Inventory Payables NWC/ Revenue* 15.3% 13.8% 13.4% 15.9% 16.0% 15.3% 678 631 610 628 563 467 443 445 496 548 521 376 -369 -463 -434 -487 -488 -469 2021 2022 2023 2024 2024 Sep 2025 Sep Jan Feb Mar Apr May Jun Jul Aug Sep Oct N
Slide 13: Outlook
Outlook 9M 2025 update | 23 October 2025
Slide 14: Near term, Medium term outlook
Near term • Risk from ongoing tariff uncertainty continues to weigh on demand • Focus on costs and cash preservation while uncertainty remains high • Diversified footprint remains a key strength in navigating uneven end-market momentum Medium term • The distribution market for speciality chemicals a
Slide 15: Innovation through formulation
Innovation through formulation